ReACT® is the first product of CellPraxis® and comprises a specific cellular formulation, indicated for the treatment of refractory angina, a chronic and disabling condition, affecting thousands of people worldwide. Aiming at clinical (pain) and functional improvement (scintigraphy) with statistical significance of these patients, positively impacting their quality of life and reducing medical costs, ReACT® is a standardized medical procedure in which a bioinfusion is performed
of a specific cell formulation (MonoCell) in the ischemic myocardium, promoting neoangiogenesis and consequent myocardial reperfusion. It was clinically tested in Brazil, with standardized inclusion criteria, accreditation and continuing medical education (Biosurgery Training Program), GCP, cGMP, GLP (Good Practices).
ReACT® is the result of the conclusion of the phase II clinical study with autologous bone marrow stem cells, made jointly by CellPraxis, Cryopraxis, Federal University of São Paulo (UNIFESP) and the University of South Florida (USF), in the U.S. ReACT® has already been presented at the V International Symposium of New Abilities in Cardiac Surgery (São Paulo, 2011) and also at the International Congress on Coronary Insufficiency (Venice, 2011) as an example of Brazil’s dynamism in biotechnology research. Currently, the product is in the stage of a multicenter phase III clinical study in Brazil.